Since then, a clinical trial has been recruiting patients with various metastatic cancers to measure CTC levels when enriched with membranous heat shock protein (mHSP70) vs EpCAM (NCT04628806). This evidence concerns the gene EPCAM and metastatic malignant neoplasm.